<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195085">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551811</url>
  </required_header>
  <id_info>
    <org_study_id>CR2100597</org_study_id>
    <nct_id>NCT00551811</nct_id>
  </id_info>
  <brief_title>Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone.</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled, 3-way Crossover Study to Evaluate the Pharmacodynamics of SB-656933-AAA Following Single Doses in Healthy Adult Subjects Undergoing Ozone Challenge.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      A study to evaluate the effect of SB-656933-AAA on the body after a single dose in subjects
      who have been challenged with ozone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of a single dose of SB-656933-AAA on ozone-induced inflammation in healthy subjects. Total number of neutrophils in sputum 6 hours after inhaling ozone.</measure>
    <time_frame>6 hours after inhaling ozone</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of white cells in sputum 6 hours after inhaling ozone. Concentration of protein in sputum. Safety of SB-656933-AAA.</measure>
    <time_frame>6 hours after inhaling ozone</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-656933-AAA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects between 18-50 years.

          -  Females should be of non-child bearing potential.

          -  Non-smoking for at least 12 months.

          -  Normal lung function.

          -  Subjects should be able to produce acceptable sputum samples.

        Exclusion Criteria:

          -  Any serious medical condition.

          -  Hepatitis B or C and/or HIV positive.

          -  Currently on regular medication except paracetamol.

          -  Body Mass Index &lt;20 or &gt;30.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 14, 2010</lastchanged_date>
  <firstreceived_date>October 29, 2007</firstreceived_date>
  <firstreceived_results_disposition_date>October 14, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>SB-656933-AAA,</keyword>
  <keyword>single dose,</keyword>
  <keyword>ozone challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
